Benzinga's Top #PreMarket Gainers

Intercept Pharmaceuticals

shares jumped 37.32% to $378.83 in pre-market trading. The company yesterday reported that the FLINT trial of obeticholic acid has been stopped early and the NASH primary endpoint has been met. Citigroup lifted the price target on the stock from $60.00 to $400.00. Conatus Pharmaceuticals

shares gained 31.02% to $12.84 in the pre-market after jumping 57.05% on Thursday. Immunomedics

soared 16.80% to $6.05 in the pre-market trading after the company announced the initiation of Phase III clinical trial of Clivatuzumab Tetraxetan in patients with pancreatic cancer. Ballard Power Systems

surged 15.87% to $2.41 in the pre-market session after the company announced a sales agreement with M-Field For Clean Baseload Power Systems.